I wonder what the impact might be if the BETonMACE trial slightly misses it's end target based on the 3 point definition but it replicates the ASSURE/SUSTAIN post hoc findings of MACE reduction within patients with cardiovascular disease, diabetes mellitus and low HDL of 77% relative risk reduction (RRR) of 77% and absolute risk reduction of 16% points (21%-5%) based on the 5 point MACE defifition. And suppose the BETonMACE findings were statistically significant at p<0.05 or even p<0.01.
I wonder if this would be a failure because the primary end point was missed slightly?
Cheers
Toinv